L-鸟氨酸乙酯.2HCl | 84772-29-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-鸟氨酸乙酯.2HCl
• 中文别名: L-鸟氨酸乙酯盐酸盐；L-鸟氨酸乙酯2盐酸盐
• 英文名称: Ethyl L-ornithine dihydrochloride
• 英文别名: ethyl (2S)-2,5-diaminopentanoate;dihydrochloride
• CAS: 84772-29-2
• 化学式: C7H18Cl2N2O2
• 分子量: 233.13
• InChiKey: FGDABGPSQJJTDH-ILKKLZGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.46
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  78.3
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

反应信息

• 作为反应物：
  描述：

  L-鸟氨酸乙酯.2HCl 、 苯甲醛 、 三乙胺 、 水 在 水 、 Brine 、 Sodium sulfate-III 作用下， 以 二氯甲烷 、 正己烷 为溶剂， 反应 18.0h， 以dibenzylidine ornithine ethyl ester is obtained as a white solid, m.p. 41.4° C.的产率得到ornithine ethyl ester
  参考文献：
  名称：

  2-(Difluoromethyl)-2,5-diaminopentanoic acid

  摘要：

  本发明涉及2-(二氟甲基)-2,5-二氨基戊酸或其药学上可接受的酸加盐，以及其制备和使用方法。

  公开号：

  US04413141A1

文献信息

• Process for the enzymatic preparation of protected and unprotected di-
  申请人：Forschungszentrum Juelich GmbH

  公开号：US05304470A1

  公开（公告）日：1994-04-19

  Protected and unprotected di- or oligopeptides are synthesized by reacting an N-terminally protected .alpha.-amino acid alkyl ester or peptide alkyl ester of the formula X--E--R.sup.1 with an amino acid or a di- or oligopeptide or a derivative thereof of the formula H.sub.2 N--Q--R.sup.2 in aqueous solution in the presence of a hydrolase, and, removing protective groups from the reaction product separated from the reaction mixture, where E is the residue of an .alpha.-amino acid or of a di- or oligopeptide, R.sup.1 is lower alkyl and X is a group which carries a charge or is polar at the pH values used for the reaction and which increases the solubility by a factor >5 compared with compounds wherein X=H, Q is the residue of an amino acid or of a di- or oligopeptide, and R.sup.2 is an optionally esterified or amidated acid group. In a preferred embodiment, the peptide or (.alpha.-)amino acid ester concentration is greater than 50 mM, wherein in a particularly preferred embodiment, the concentration ranges from 100 to 1000 mM with approximately comparable nucleophile and electrophile concentrations. The preferred substrate/enzyme ratios are >10.sup.5 M/M or >10.sup.3 M/M when papain is employed. Phthalyl, maleyl or citraconyl radicals and their derivatives or N-betainyl compounds are envisaged for use radicals (X) in the electrophilic component.

  保护和未保护的二肽或寡肽通过在水溶液中存在水解酶的情况下，通过反应公式X-E-R.sup.1的N-端保护的α-氨基酸烷基酯或肽烷基酯与公式H.sub.2 N-Q-R.sup.2的氨基酸或二肽或寡肽或其衍生物反应而合成，并从反应混合物分离的反应产物中去除保护基，其中E是α-氨基酸或二肽或寡肽的残基，R.sup.1是较低的烷基，X是在反应使用的pH值下带电荷或是极性的基团，与X=H的化合物相比，其溶解度提高了大于5倍，Q是氨基酸或二肽或寡肽的残基，R.sup.2是可选的酯化或酰胺化酸基。在一种优选实施例中，肽或（α-）氨基酸酯的浓度大于50 mM，在一种特别优选实施例中，浓度范围从100到1000 mM，核苷酸亲核剂和电子亲和剂浓度大致相当。所需的底物/酶比为> 10.sup.5 M/M或> 10.sup.3 M/M，当使用木瓜蛋白酶时。在电子亲和成分中，考虑使用邻苯二甲酸酐基，马来酰基或顺-己烯三酸酐基及其衍生物或N-甜菜碱化合物的自由基（X）。
• CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE
  申请人：Seikagaku Corporation

  公开号：EP3246037A1

  公开（公告）日：2017-11-22

  Provided is a chondroitin sulfate derivative having a structure cross-linked with a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

  本发明提供了一种硫酸软骨素衍生物，其结构与多价胺中的一个基团交联。还提供了一种含有该硫酸软骨素衍生物的组合物。还提供了一种用于治疗眼病的制剂和方法，该制剂和方法对角膜上皮疾病和/或干眼症具有治疗效果。
• DEGRADABLE SPIRAL COATED STENT WITH CONTROLLABLE GRADIENT, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Zhuhai Ruizhan Biomaterials Co., Ltd.

  公开号：EP3818995A1

  公开（公告）日：2021-05-12

  Disclosed are a spiral coated stent with controllable gradient degradation, a preparation method thereof and an application thereof. The spiral coated stent with controllable gradient degradation is composed of a degradable medical polyurethane and a degradable magnesium alloy material, wherein the degradable medical polyurethane contains a following chemical structure: PCL-PEG-PCL, wherein a molecular weight of the PEG is 200 to 1,000 and the molecular weight of the PCL is 200 to 10,000, and the degradable magnesium alloy material is of a spiral stent structure; and physical properties of the spiral coated stent with controllable gradient degradation need to satisfy the following technical parameters that: a breaking strength needs to be no less than 1 N, a pressure resistance needs to be no less than 2 N, and a degradation characteristic of the magnesium alloy after surface treatment shows gradient degradation with different time.

  本发明公开了一种可控梯度降解螺旋涂层支架、其制备方法及其应用。可控梯度降解螺旋涂层支架由可降解医用聚氨酯和可降解镁合金材料组成，其中可降解医用聚氨酯包含以下化学结构：PCL-PEG-PCL，其中PEG的分子量为200～1000，PCL的分子量为200～10000，可降解镁合金材料为螺旋支架结构；可控梯度降解螺旋涂层支架的物理性能需满足以下技术参数：断裂强度不小于1N，抗压强度不小于2N，镁合金表面处理后的降解特性随时间变化呈梯度降解。
• CROSS-LINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE
  申请人：Seikagaku Corporation

  公开号：EP3831394A1

  公开（公告）日：2021-06-09

  Provided is a chondroitin sulfate derivative having a structure cross-linked with a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye

  本发明提供了一种硫酸软骨素衍生物，其结构与多价胺中的一个基团交联。还提供了一种含有该硫酸软骨素衍生物的组合物。还提供了一种用于治疗眼疾的制剂和方法，该制剂和方法对角膜上皮疾病和/或干眼症具有治疗效果。
• Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease
  申请人：SEIKAGAKU CORPORATION

  公开号：US10420796B2

  公开（公告）日：2019-09-24

  Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

  本发明提供了一种硫酸软骨素衍生物，该衍生物通过多价胺中的一个基团具有交联结构。还提供了一种含有该硫酸软骨素衍生物的组合物。还提供了一种用于治疗眼疾的制剂和方法，该制剂和方法对角膜上皮疾病和/或干眼症具有治疗效果。